IDH1-VAC (IDH1 R132H Peptide Vaccine)
Sources
publication, as of 2026-11-07
https://www.nature.com/articles/s41586-021-03363-z
Platten M et al. A vaccine targeting mutant IDH1 in newly diagnosed glioma (NOA-16, NCT02454634). Nature 2021;592:463-468 (abstract via search record)
Brief source I13
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT02454634
Targeting IDH1R132H in WHO Grade III-IV IDH1R132H-mutated Gliomas by a Peptide Vaccine - a Phase I Safety, Tolerability and Immunogenicity Multicenter Trial (NOA-16)
ClinicalTrials.gov API v2 record, retrieved 2026-11-07
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT07888647
IDH1-vac in Patients With Newly Diagnosed IDH1R132H-positive High-grade Astrocytomas - a Randomized Double-blind Phase 2 Study
ClinicalTrials.gov API v2 record, retrieved 2026-11-07
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT07877415
A Multicenter Safety and Immunogenicity Window-of-opportunity Phase 1 Interventional Trial Assessing the Combination of IDH1 Vaccine (IDH1-vac) and Vorasidenib in Adult Patients With Recurrent IDH1R132H-mutant Astrocytoma, Grade 2 - 4 (iVOCAL)
ClinicalTrials.gov API v2 record, retrieved 2026-11-07